Project Grant HT94252510521
Award Date
7/1/25
Completion Date
9/30/28
Dollars Obligated
$7.7M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Fountain Hill, PA 18015, USA
Similar Awards
This $315,958 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Rush University Medical Center to investigate the neural underpinnings of the relationship between cognitive and gait dysfunction in Fragile X-associated Tremor/Ataxia Syndrome (FXTAS). The award period runs from September 30, 2024 to September 29, 2026. This research aims to transform health care for...
The Department of the Army Medical Command awarded a $1,324,049 Project Grant to the University of Wisconsin-Madison through the Military Medical Research and Development program (CFDA 12.420) to identify neuronal signatures that distinguish Fragile X syndrome (FXS) patients with distinct electroencephalogram (EEG) phenotypes. The four-year award beginning August 1, 2022 will support research to investigate medical solutions for the battlefield by transforming healthcare through innovative...
This Project Grant award, valued at $1,971,504.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The purpose of the award is to conduct a crossover randomized controlled trial (RCT) evaluating the effectiveness of an individualized progressive treatment for expanding sound tolerance in adults with autism spectrum disorder. The principal awardee is the University of Central Florida Board of Trustees, Office of...
The University of Illinois was awarded an $872,300 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) to define the developmental time course and therapeutic window for sensory circuit impairments in a rat model of Fragile X syndrome. The three-year award beginning April 15, 2023 will support basic research investigating medical solutions for sensory processing deficits observed in those with Fragile X, with the...
The Defense Health Agency awarded a $2.14 million project grant under the Military Medical Research and Development program (CFDA 12.420) to the Foundation For Advancing Veterans Health Research, a non-profit organization and foundation. The funding supports a randomized clinical trial evaluating the effectiveness of quetiapine in reducing polypharmacy among patients with post-concussive syndrome in San Antonio, TX. As a subrecipient, the Foundation also provides staffing, biostatistics,...
The federal Project Grant award, totaling $6,663,794.00 and effective September 30, 2024, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports the "PRECISIE RTD TRIAL: PRECISION WITH RETURN-TO-DUTY DECISIONS IN THE MILITARY" research initiative, which aims to transform healthcare for military service members. The primary awardee, The Geneva Foundation, will conduct advanced biomedical research and...
The federal Project Grant award in the amount of $564,901.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research to develop a drug delivery strategy using exosomes as nanocarriers to target the brainstem. This multi-year award, with a project period from September 1, 2024 to August 31, 2027, will be performed by the Mayo Clinic, a leading non-profit academic medical center. The research aims to explore innovative...
The Defense Health Agency awarded a $1,973,398 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to Azevan Pharmaceuticals Inc. in Bethlehem, PA. The grant supports the development of a new drug to prevent the effects of mild traumatic brain injury (TBI) or concussion. The research project will be conducted over a 2-year period from June 2024 to June 2026. The goal is to advance the development of an innovative medical solution to address this critical...
The federal Project Grant award for "A NOVEL TRANSLATIONAL MECHANISM UNDERLYING TSC PATHOPHYSIOLOGY" was made by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The $793,572 award was granted to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, to conduct advanced biomedical research focused on transforming healthcare for military service members and the broader public. This research...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded Scripps Research Institute, a nonprofit biomedical research organization, a $529,125 project grant to investigate microglia dysfunction in MEF2C deficiency autism spectrum disorder with the goal of discovering targeted therapies. This 3-year award, effective September 30, 2024, will fund research aimed at improving the health and care of military service members, veterans, and their families...